Abstract:Eight genetically distinct families of the enzyme carbonic anhydrase (CA, EC 4.2.1.1) were described in organisms allover the phylogenetic tree. They catalyze the hydration of CO2 to bicarbonate and protons, and are involved in pH regulation, chemosensing and metabolism. The 15 α-CA isoforms present in humans are pharmacological drug targets known for decades, their inhibitors being used as diuretics, antiglaucoma, antiepileptic or antiobesity drugs, as well as for the management of acute mountain sickness, idiopathic intracranial hypertension and recently, as antitumor theragnostic agents. Other potential applications include the use of CA inhibitors (CAIs) in inflammatory conditions, cerebral ischemia, neuropathic pain, or for Alzheimer's/Parkinson's disease management. CAs from pathogenic bacteria, fungi, protozoans and nematodes started to be considered as drug targets in recent years, with notable advances registered ultimately. CAIs have a complex multipharmacology probably unique to this enzyme, which has been exploited intensely but may lead to other relevant applications in the future, due to the emergence of drug design approaches which afforded highly isoform-selective compounds for most α-CAs known to date. They belong to a multitude of chemical classes (sulfonamides and isosteres, (iso)coumarins and related compounds, mono- and dithiocarbamates, selenols, ninhydrines, boronic acids, benzoxaboroles, etc). The polypharmacology of CAIs will also be discussed since drugs originally discovered for the treatment of non-CA related conditions (topiramate, zonisamide, celecoxib, pazopanib, thiazide and high-ceiling diuretics) show efective inhibition against many CAs, which led to their repurposing for diverse pharmacological applications. Significance Statement Carbonic anhydrase inhibitors have multiple pharmacologic applications as diuretics, antiglaucoma, antiepileptic, antiobesity, anti-acute mountain sickness, anti-idiopathic intracranial hypertension and as antitumor drugs. Their use in inflammatory conditions, cerebral ischemia, neuropathic pain, or neurodegenerations started to be investigated recently. Parasite carbonic anhydrases are also drug targets for antiinfectives with novel mechanisms of action which can by pass drug resistance to commonly used such agents. Drugs discovered for the management of other conditions that effectively inhibit these enzymes exert interesting polypharmacologic effects.

Applications of carbonic anhydrases inhibitors in renal and central nervous system diseases

Multi- and poly-pharmacology of carbonic anhydrase inhibitors

Advances in structure-based drug discovery of carbonic anhydrase inhibitors

An update on drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors

Carbonic anhydrase inhibition/activation: trip of a scientist around the world in the search of novel chemotypes and drug targets

Carbonic anhydrases: Moiety appended derivatives, medicinal and pharmacological implications

Drug interactions of carbonic anhydrase inhibitors and activators

Carbonic Anhydrases as Potential Targets Against Neurovascular Unit Dysfunction in Alzheimer's Disease and Stroke

Carbonic anhydrase, its inhibitors and vascular function

Bacterial, fungal and protozoan carbonic anhydrases as drug targets

Exploring the multiple binding modes of inhibitors to carbonic anhydrases for novel drug discovery

Biomedical applications of prokaryotic carbonic anhydrases: an update

An overview of novel antimicrobial carbonic anhydrase inhibitors

Click chemistry approaches for developing carbonic anhydrase inhibitors and their applications

The carbonic anhydrase enzymes as new targets for the management of neglected tropical diseases

Neuroprotective Effects of Carbonic Anhydrase Inhibition and Cyclic Adenosine Monophosphate Activation in Mouse Model of Transient Global Cerebral Ischemia and Reperfusion

Is carbonic anhydrase inhibition useful as a complementary therapy of Covid-19 infection?

Carbonic anhydrase and bacterial metabolism: a chance for antibacterial drug discovery

Thiosemicarbazone-benzene Sulfonamide Derivatives as Human Carbonic Anhydrases Inhibitors: Synthesis, Characterization, and In silico Studies

5‐[2‐(N‐(substituted Phenyl)acetamide)]amino‐1,3,4‐thiadiazole‐2‐sulfonamides As Selective Carbonic Anhydrase II Inhibitors with Neuroprotective Effects

Challenges for developing bacterial CA inhibitors as novel antibiotics